PGS Publication: PGP000156

Publication Information (EuropePMC)
Title A genome-wide association study of prostate cancer in Latinos.
PubMed ID 31226226(Europe PMC)
doi 10.1002/ijc.32525
Publication Date July 3, 2019
Journal Int J Cancer
Author(s) Du Z, Hopp H, Ingles SA, Huff C, Sheng X, Weaver B, Stern M, Hoffmann TJ, John EM, Van Den Eeden SK, Strom S, Leach RJ, Thompson IM, Witte JS, Conti DV, Haiman CA.
Released in PGS Catalog: March 22, 2021

Associated Polygenic Score(s)

Filter PGS by Participant Ancestry
Individuals included in:
G - Source of Variant Associations (GWAS)
D - Score Development/Training
E - PGS Evaluation
List of ancestries includes:
Display options:
Ancestry legend
Multi-ancestry (including European)
Multi-ancestry (excluding European)
African
East Asian
South Asian
Additional Asian Ancestries
European
Greater Middle Eastern
Hispanic or Latin American
Additional Diverse Ancestries
Not Reported

PGS Developed By This Publication

Polygenic Score ID & Name PGS Publication ID (PGP) Reported Trait Mapped Trait(s) (Ontology) Number of Variants Ancestry distribution
GWAS
Dev
Eval
 Scoring File (FTP Link)
PGS000751
(PRS_PrCa_EuropeanWeighted)
 PGP000156 |
Du Z et al. Int J Cancer (2019)
 Prostate cancer prostate carcinoma 178
-
 https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000751/ScoringFiles/PGS000751.txt.gz

Performance Metrics

Disclaimer: The performance metrics are displayed as reported by the source studies. It is important to note that metrics are not necessarily comparable with each other. For example, metrics depend on the sample characteristics (described by the PGS Catalog Sample Set [PSS] ID), phenotyping, and statistical modelling. Please refer to the source publication for additional guidance on performance.

PGS Performance
Metric ID (PPM) 		Evaluated Score PGS Sample Set ID
(PSS) 		Performance Source Trait PGS Effect Sizes
(per SD change) 		Classification Metrics Other Metrics Covariates Included in the Model PGS Performance:
Other Relevant Information
PPM001907 PGS000751
(PRS_PrCa_EuropeanWeighted)
 PSS000953|
Hispanic or Latin American Ancestry|
4,324 individuals
 PGP000156 |
Du Z et al. Int J Cancer (2019)
 Reported Trait: Prostate cancer — — Odds ratio (OR, top 10% vs. middle 50%): 3.1 [2.55, 3.76] Age, study, PCs(1-10) Only 176 variants of the original 181 variants were utilised as 5 variants did not meet a MAF  ≥  0.001 and imputation r^2  ≥ 0.3 in Latino men.
PPM001908 PGS000751
(PRS_PrCa_EuropeanWeighted)
 PSS000953|
Hispanic or Latin American Ancestry|
4,324 individuals
 PGP000156 |
Du Z et al. Int J Cancer (2019)
 Reported Trait: Prostate cancer — — Odds ratio (OR, top 1% vs. middle 50%): 4.02 [2.46, 6.55] Age, study, PCs(1-10) Only 176 variants of the original 181 variants were utilised as 5 variants did not meet a MAF  ≥  0.001 and imputation r^2  ≥ 0.3 in Latino men.
PPM001909 PGS000751
(PRS_PrCa_EuropeanWeighted)
 PSS000953|
Hispanic or Latin American Ancestry|
4,324 individuals
 PGP000156 |
Du Z et al. Int J Cancer (2019)
 Reported Trait: Prostate cancer — — Odds ratio (OR, bottom 10% vs. middle 50%): 0.38 [0.28, 0.51] Age, study, PCs(1-10) Only 176 variants of the original 181 variants were utilised as 5 variants did not meet a MAF  ≥  0.001 and imputation r^2  ≥ 0.3 in Latino men.
PPM001910 PGS000751
(PRS_PrCa_EuropeanWeighted)
 PSS000953|
Hispanic or Latin American Ancestry|
4,324 individuals
 PGP000156 |
Du Z et al. Int J Cancer (2019)
 Reported Trait: Prostate cancer — — Odds ratio (OR, bottom 1% vs. middle 50%): 0.25 [0.09, 0.67] Age, study, PCs(1-10) Only 176 variants of the original 181 variants were utilised as 5 variants did not meet a MAF  ≥  0.001 and imputation r^2  ≥ 0.3 in Latino men.

Evaluated Samples

PGS Sample Set ID
(PSS) 		Phenotype Definitions and Methods Participant Follow-up Time Sample Numbers Age of Study Participants Sample Ancestry Additional Ancestry Description Cohort(s) Additional Sample/Cohort Information
PSS000953 In set 1 (1034 cases), prostate cancer cases were identified by linking with the cancer registries in Hawaii and California. In set 2 (1192 cases) cases were indiviuals with prostate cancer determined by cancer diagnosis, enrollment in prostate cancer studies at University of Texas M.D. Ancerson Cancer Centre or by biposy confirmation. —
[
  • 2,226 cases
  • , 2,098 controls
]
,
100.0 % Male samples
 — Hispanic or Latin American — LAAPC, MDA, MEC, SABOR —